Anktiva Dosage
Generic name: NOGAPENDEKIN ALFA INBAKICEPT-PMLN 400ug in 0.4mL
Dosage form: solution, for intravesical use
Drug class: Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on May 9, 2024.
Recommended Dosage
For Intravesical Use Only. Do NOT administer by subcutaneous or intravenous or intramuscular routes.
- For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if complete response is not achieved at month 3.
- For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses). For patients with an ongoing complete response at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.
The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.
Preparation and Administration
Preparation of Agent
See BCG Prescribing Information for information on preparation and handling of BCG.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution is clear to slightly opalescent and colorless to slightly yellow. Discard the vial if visible particles are observed.
Draw 0.4 mL of ANKTIVA into a small syringe and using aseptic technique add to the saline containing the BCG suspension that has been prepared following the instructions provided in the Prescribing Information for BCG. Mix the suspension gently. Using a 60-mL syringe connected to an appropriate size needle, withdraw the ANKTIVA BCG mixture to a final volume of 50 mL.
If the admixture of ANKTIVA in combination with BCG is not used immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) and use within 2 hours. Unused solution of admixture should be discarded after 2 hours.
Treatment
The admixture of ANKTIVA in combination with BCG is instilled into the bladder via a catheter. After instillation is complete, the catheter is removed. The ANKTIVA in combination with BCG admixture is retained in the bladder for 2 hours and then voided. Patients unable to retain the suspension for 2 hours should be allowed to void sooner, if necessary. Do not repeat the dose if the patient voids before 2 hours.
See BCG Prescribing Information for information on retention in the bladder and patient positioning during bladder instillation.
More about Anktiva (nogapendekin alfa inbakicept)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Padcev
Padcev (enfortumab vedotin) is an antibody-drug conjugate that is given as an intravenous infusion ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
Enfortumab vedotin
Enfortumab vedotin systemic is used for bladder cancer, urothelial carcinoma
Mitomycin
Mitomycin systemic is used for anal cancer, bladder cancer, pancreatic cancer, stomach cancer ...
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.